In a phase I clinical trial, the safety, tolerance, and pharmacokinetic effects of bremelanotide were assessed in both male and female participants
Key findings from this phase 2 obesity trial included: Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks Dose-dependent reductions in body weight across all active treatment arms Significant reductions in waist circumference, blood pressure, and lipid parameters Improvements in fasting glucose and insulin resistance markers A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management
over 80% of patients who have received a kidney transplant will develop skin cancer within 20 years
The Indian pharmaceutical landscape is witnessing a major disruption with the patent expiry of Semaglutide (GLP-1 receptor agonist) in March 2026
Benefits Triple L-Carnitine Formula: Combines three forms of L-carnitine (acetyl, fumarate, and tartrate) for enhanced absorption and effectiveness
